Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Report 2026

Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Overview

• Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms market size has reached to $2.14 billion in 2025 • Expected to grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 20.2% • Growth Driver: Rising Volume Of Adverse Event (AE) Reports Driving The Market Growth Due To Increasing Regulatory Reporting Requirements • Market Trend: Technological Advancements In AI-Enabled Pharmacovigilance Systems Transforming End-To-End Drug Safety Workflows • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market?

Artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms are software-based systems that leverage machine learning, natural language processing, and data analytics to detect, assess, monitor, and prevent adverse drug reactions and safety risks associated with pharmaceutical products. These platforms process large-scale clinical, real-world, and regulatory data to improve signal detection, automate safety reporting, and support regulatory compliance throughout the drug lifecycle. The main components of artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms include software platforms and services. Software platforms refer to AI-enabled solutions that automate the collection, analysis, monitoring, and reporting of adverse drug events to enhance drug safety and regulatory compliance. These platforms are deployed through cloud-based, on-premise, and hybrid models and are adopted by large enterprises and small and medium-sized enterprises. The various applications involved are case processing and management, signal detection and management, risk management and reporting, and regulatory compliance, and they are used by several end users such as pharmaceutical companies, biotechnology companies, contract research organizations, regulatory authorities, healthcare providers, and academic and research institutes.

What Is The Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Growth Forecast?

The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market size is expected to see exponential growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to integration of ai into drug safety surveillance systems, expansion of real-world evidence based pharmacovigilance, increasing regulatory demand for automated compliance reporting, growth in predictive safety analytics platforms, rising adoption of cloud-based drug safety monitoring systems. Major trends in the forecast period include AI-powered adverse event detection systems, natural language processing based safety signal extraction, predictive pharmacovigilance analytics platforms, real-time drug safety monitoring using real-world data, automated regulatory safety reporting systems.

Global Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Segmentation

1) By Component: Software Platforms; Services 2) By Deployment Mode: Cloud-Based; On-Premise; Hybrid 3) By Enterprise Size: Large Enterprises; Small And Medium-Sized Enterprises 4) By Application: Case Processing And Management; Signal Detection And Management; Risk Management And Reporting; Regulatory Compliance 5) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations; Regulatory Authorities; Healthcare Providers; Academic And Research Institutes Subsegments: 1) By Software Platforms: Adverse Event Monitoring Software Platforms; Natural Language Processing Based Pharmacovigilance Platforms; Predictive Analytics And Safety Intelligence Platforms 2) By Services: Implementation And Integration Services; Consulting And Regulatory Compliance Services; Artificial Intelligence Model Training And Validation Services; Maintenance And Support Services

What Is The Driver Of The Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market?

The rising volume of adverse event (AE) reports is expected to propel the growth of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market going forward. Adverse event (AE) reports refer to documented cases of unintended and harmful reactions or outcomes experienced after the use of a medical product or drug. The volume of adverse event (AE) reports is increasing due to stricter regulatory requirements that compel healthcare providers and pharmaceutical companies to report a wider range of safety issues more frequently and in greater detail. Artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms process adverse event (AE) reports by aggregating data from clinical systems, electronic health records, and real-world sources to detect and classify safety signals, automate case processing, and improve regulatory decision-making speed and accuracy. For instance, February 2024, according to the Analysis Of Adverse Drug Reactions 2023 Report by the Department of Health Abu Dhabi, a UAE-based regulatory body, a total of 1,522 adverse drug reaction reports were submitted to the pharmacovigilance program between January and December 2023, representing a 235% increase compared to the average annual number of reports recorded in previous years. Therefore, the rising volume of adverse event (AE) reports is driving the growth of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms industry.

Key Players In The Global Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market

Major companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are Microsoft Corporation; International Business Machines Corporation; Accenture plc; Oracle Corporation; Cognizant Technology Solutions Corporation; IQVIA Holdings Inc.; Wipro Limited; ICON Public Limited Company; Fortrea; Clarivate Plc; Genpact Limited; Veeva Systems Inc.; ArisGlobal; Certara Inc.; Tempus AI Inc.; Komodo Health Inc.; Elsevier B.V.; Navitas Life Sciences; PrimeVigilance; Ennov Group SAS; Cloudbyz Inc.; Phesi; Medrio Inc.; Genomics England Limited

Global Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Trends and Insights

Major companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are focusing on developing innovative treatments, such as agentic AI-driven pharmacovigilance platforms, to enhance automated adverse event detection, regulatory compliance, and efficiency in drug safety monitoring by reducing manual case-processing workloads and improving signal detection accuracy. Agentic AI pharmacovigilance platforms are advanced software systems that use domain-trained machine learning models, natural language processing, and workflow orchestration to independently perform and coordinate safety tasks such as case intake, literature surveillance, signal detection, and aggregate reporting. For instance, in May 2026, RxLogix Systems Inc., a US-based pharmacovigilance solutions company, launched the upgraded PVOne.AI platform, an AI-enabled pharmacovigilance system that integrates agentic AI capabilities to automate and orchestrate end-to-end drug safety workflows. The platform operates across case intake, adverse event monitoring, literature surveillance, signal detection, aggregate reporting, and risk management, leveraging contextual reasoning and domain-trained models to support regulatory-grade decision-making. It also includes human-in-the-loop controls to ensure compliance with FDA and global pharmacovigilance standards while significantly reducing manual effort in case processing by up to 80%, improving reviewer productivity by up to 75%, and enabling up to 50% touchless workflows by minimizing repetitive tasks and enhancing prioritization of safety signals in large-scale pharmaceutical datasets.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market?

In October 2024, EVERSANA Inc., a US-based Pharmaceutical Manufacturing company that specializes in providing comprehensive AI-driven platforms and solutions for drug safety and pharmacovigilance (PV), partnered with Oracle Corporation to enhance pharmacovigilance and drug safety capabilities. With this partnership, EVERSANA Inc. entered into a strategic collaboration agreement with Oracle Corporation to implement Oracle Argus Cloud Service, enabling AI-powered automation, workflow optimization, and touchless processing to improve safety case management, regulatory compliance, and global patient support services across the life sciences industry. Oracle Corporation is a US-based technology company specializing in cloud infrastructure, enterprise software, and healthcare and life sciences solutions.

Regional Outlook

North America was the largest region in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market?

The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market includes revenues earned by entities by providing services such as software licensing and subscription, cloud-based pharmacovigilance solutions, adverse event detection and reporting systems, data integration and interoperability solutions, predictive safety analytics, regulatory compliance support, system customization and integration, maintenance and technical support, consulting, and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Report 2026?

The artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.